Portage Biotech (PRTG)

• Market cap: $4.29M
• 1 day: 3.54%
• 5 days: -12.23%
• 1 month: -34.66%
• 3 months: 16.86%
• 6 months: -19.96%
• Year to date: -89.18%
• 1 year: -85.70%
• 5 years: -99.44%
• 10 years: -99.44%

About: Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Employees: 7

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

41% more capital invested

Capital invested by funds: $558K [Q2] → $788K (+$230K) [Q3]

0.07% more ownership

Funds ownership: 11.34% [Q2] → 11.41% (+0.07%) [Q3]

41% less funds holding

Funds holding: 22 [Q2] → 13 (-9) [Q3]

75% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 12

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 10